A practical reference on actin-binding motif: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
=== Ribosome-mediated attenuation === In this situation RNA polymerase is dependent on (lagging) ribosome activity; if the ribosome pauses due to insufficient charged tRNA then the anti-terminator structure is favoured. The canonical attenuator example of the trp operon uses this mechanism in E. coli. Similar regulatory mechanisms have been found in many amino acid biosynthetic operons.
== Reactions == Menthol reacts in many ways like a normal secondary alcohol. It is oxidised to menthone by oxidising agents such as chromic acid, dichromate, or by calcium hypochlorite, in a green chemistry route. Under some conditions the oxidation using Cr(VI) compounds can go further and break open the ring. Menthol is easily dehydrated to give mainly 3-menthene, by the action of 2% sulfuric acid. Phosphorus pentachloride (PCl5) gives menthyl chloride.
=== Artificial synthesis === Prostacyclin can be synthesized from the methyl ester of prostaglandin F2α. After its synthesis, the drug is reconstituted in saline and glycerin. Because prostacyclin is so chemically labile, quantitation of their inactive metabolites, rather than the active compounds, is used to assess their rate of synthesis.
=== Diabetes === Cellular uptake of glucose occurs in response to insulin signals, and glucose is subsequently broken down through glycolysis, lowering blood sugar levels. However, insulin resistance or low insulin levels seen in diabetes result in hyperglycemia, where glucose levels in the blood rise and glucose is not properly taken up by cells. Hepatocytes further contribute to this hyperglycemia through gluconeogenesis. Glycolysis in hepatocytes controls hepatic glucose production, and when glucose is overproduced by the liver without having a means of being broken down by the body, hyperglycemia results.
On 26 October 1985, the government extended the emergency to the western Cape, where it said that the situation had reached a "state of pre-insurrection"; confrontations there had heightened since August, when the state had suppressed a planned march on Pollsmoor Prison, where Nelson Mandela was being held. In all, the emergency degree was applied to detain between 8,000 and 12,000 people without trial.
Sources: en.wikipedia.org
=== 1950s === 1950: Isabella Abbott became the first Native Hawaiian woman to receive a PhD in any science; hers was in botany. 1950: Esther Lederberg was the first to isolate lambda bacteriophage, a DNA virus, from Escherichia coli K-12. 1952: Grace Hopper completed what is considered to be the first compiler, a program that allows a computer user to use English-like words instead of numbers. It was known as the A-0 compiler. 1956: The Wu experiment was a nuclear physics experiment conducted in 1956 by the physicist Chien-Shiung Wu, born in China but having become an American citizen in 1954, in collaboration with the Low Temperature Group of the US National Bureau of Standards. That experiment showed that parity could be violated in weak interaction.
In Situ NMR: In situ NMR enables real-time observation of chemical and structural changes in batteries while they are operating. This is particularly important for studying transient species that only exist under working conditions, such as certain intermediate reaction products. In situ NMR has become a critical tool for understanding processes like lithium and sodium plating and dendrite formation during battery cycling. Ex Situ NMR: Ex situ NMR is used after the battery has been disassembled, allowing for high-resolution analysis of battery components. It is often employed to study a wide range of nuclei, including 1H, 2H, 6Li, 7Li, 13C, 15N, 17O, 19F, 25Mg, 29Si, 31P, 51V, 133Cs. Many of these nuclei are quadrupolar or present in low abundance, making them difficult to detect. However, ex situ NMR benefits from better sensitivity and narrower linewidths, which can be further improved by employing larger sample volumes, higher magnetic fields, or magic angle spinning (MAS).
Non-selective beta-blockers: propranolol, nadolol, timolol Beta-1-selective beta-blockers: atenolol, bisoprolol, metoprolol, esmolol Beta-blockers with vasodilating effect: labetalol, carvedilol, nebivolol Beta-blockers with intrinsic sympathomimetic activity: acebutolol, pindolol Some common side effects include increased airway resistance for non-selective beta-blockers, exacerbation of peripheral vascular diseases, and hypotension Beta-blockers are contraindicated in patients with second- or third-degree atrioventricular block. In particular, beta-blockers with intrinsic sympathomimetic activity are contraindicated in patients with myocardial infarction, heart failure or severe bradycardia. Beta-blockers should be used with caution in patients with asthma or chronic obstructive pulmonary disease (COPD) due to bronchoconstriction, and in patients with diabetes mellitus (DM) due to masking of hypoglycaemia.
=== Cultural outlook === Irish society during this period was extremely Roman Catholic, with Roman Catholic thinkers promoting anti-capitalist, anti-communist, anti-Protestant, anti-Masonic, and antisemitic views in Irish society. Through the works of priests such as Edward Cahill, Richard Devane, and Denis Fahey, Irish society saw capitalism, individualism, communism, private banking, the promotion of alcohol, contraceptives, divorce, and abortion as the pursuits of the old 'Protestant-elite' and Jews, with their efforts combined through the Freemasons. Denis Fahey described Ireland as "the third most Masonic country in the world" and saw this alleged order as contrary to the creation of an independent Irish State.
Sources: en.wikipedia.org
On February 4, 2025, United States president Donald Trump proposed a US takeover of the Gaza Strip and the relocation of its Palestinian inhabitants. Officially known as the Gaza Reconstitution, Economic Acceleration and Transformation Trust (or GREAT Trust), the proposal was announced by Trump during a press conference between him and Israeli prime minister Benjamin Netanyahu, and occurred during a ceasefire in the Gaza war, fought between Israel and Hamas-led Palestinian militants. Trump expressed his vision to redevelop the territory into the "Riviera of the Middle East". The proposal called for the forced displacement of approximately two million Palestinians to neighboring lands, and would also have required the removal of over 50 million tonnes of debris and unexploded ordnance. When asked how the territory would be acquired, Trump claimed the US would "take it". The proposal received negative receptions from several nations and organizations, contrasting with strong support from Netanyahu.
=== CRF1 === Agonists: Cortagine Corticorelin Corticotropin-releasing hormone Sauvagine Stressin I Urocortin Antagonists: Antalarmin Astressin-B CP-154,526 Emicerfont Hypericin LWH-234 NBI-27914 NBI-74788 Pexacerfont R-121919 TS-041 Verucerfont
=== Other countries === Legislation has been implemented by Japan, Singapore, and Australia that offers subsidies and other incentives to encourage the development of drugs that treat orphan diseases.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.